Get the Stockscreener App
6.02
1.63%
-0.10
Scilex Holding Company stock is traded at $6.02, with a volume of 108.70K.
It is down -1.63% in the last 24 hours and down -42.67% over the past month.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
See More
Previous Close:
$6.12
Open:
$6.06
24h Volume:
108.70K
Relative Volume:
2.27
Market Cap:
$986.90K
Revenue:
$46.74M
Net Income/Loss:
$-114.33M
P/E Ratio:
-4.6667
EPS:
-1.29
Net Cash Flow:
$-21.04M
1W Performance:
-31.17%
1M Performance:
-42.67%
6M Performance:
-81.83%
1Y Performance:
-85.30%
1-Day Range:
$5.80
$6.32
1-Week Range:
$5.80
$7.64
52-Week Range:
$5.80
$80.50
Scilex Holding Company Stock (SCLX) Company Profile
Name
Scilex Holding Company
Sector
Industry
Phone
(650) 516-4310
Address
960 SAN ANTONIO ROAD, PALO ALTO
Compare SCLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCLX
Scilex Holding Company
|
6.02 | 986.90K | 46.74M | -114.33M | -21.04M | -1.29 |
|
LLY
Lilly Eli Co
|
839.96 | 677.40B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
157.47 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
|
ABBV
Abbvie Inc
|
172.99 | 316.82B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
58.08 | 293.24B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.86 | 216.19B | 51.72B | 11.94B | 13.81B | 5.88 |
Scilex Holding Company Stock (SCLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-25 | Initiated | D. Boral Capital | Buy |
| Oct-16-24 | Initiated | Alliance Global Partners | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-16-23 | Initiated | B. Riley Securities | Buy |
| Oct-13-23 | Initiated | B. Riley Securities | Buy |
| Oct-09-23 | Initiated | H.C. Wainwright | Buy |
View All
Scilex Holding Company Stock (SCLX) Latest News
Scilex Gets FDA Orphan Drug Label for Colchicine for Pericarditis - marketscreener.com
Scilex Gets Orphan Drug Designation for Its Version of Colchicine - MarketScreener
Scilex Holding Company Announces FDA Has Approved Our - GlobeNewswire
Scilex Holding announces 1-for-35 reverse stock split By Investing.com - Investing.com Canada
What Does the Market Think About Scilex Holding? - Benzinga
Scilex Holding announces 1-for-35 reverse stock split - Investing.com Australia
Canada approves Scilex’s migraine solution ELYXYB - Investing.com
Scilex Holding Company Announces Approval of a New Drug - GlobeNewswire
Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®’s Acute Treatment of Migraine With or Witho - Yahoo Finance
Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination - GlobeNewswire Inc.
Scilex downgraded to Hold from Buy at D. Boral Capital - Yahoo Finance
Scilex to Implement 1-for-35 Reverse Stock Split - marketscreener.com
Scilex Announces Reverse Stock Split to Meet Nasdaq Rules - TipRanks
Scilex Holding Company Announces 1-For-35 Reverse Stock Split - MarketScreener
Scilex Holding Company Announces 1-for-35 Reverse Stock Split - GlobeNewswire
Is Scilex Holding Company (NASDAQ: SCLX) Still A Good Investment? - stocksregister.com
Scilex (NASDAQ:SCLX) Stock Price Up 1.8% – Here’s What Happened - Defense World
Scilex Holding Company Has Appealed Lower Court Decision to - GlobeNewswire
Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva - The Manila Times
Hogs Weakness Extending to Wednesday - The Globe and Mail
AUDNZD Finally Turning Bearish? - The Globe and Mail
Denali Capital Acquisition Pushes Merger Deadline With Extra Funding -March 12, 2025 at 04:44 am EDT - Marketscreener.com
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination - The Manila Times
Scilex Holding Company Announces Change in Record Date for - GlobeNewswire
Scilex Announces New Record Date for Preferred Stock - TipRanks
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, - The Manila Times
Scilex Holding Company Announces Change of Record Date for Preferred Stock Dividend - Nasdaq
Scilex Holding Ends Sales Agreement with Brokers - TipRanks
Oramed Pharmaceuticals Issues Letter to Shareholders – Company Announcement - Financial Times
Scilex Holding Company (NASDAQ:SCLX) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
Breakeven Is Near for Scilex Holding Company (NASDAQ:SCLX) - Yahoo Canada Finance
Scilex Holding ends sales agreement, shares details By Investing.com - Investing.com Australia
Scilex Holding Says Terminates Sales Agreement With B. Riley, Cantor Fitzgerald, H.C. Wainwright Effective March 5 - Marketscreener.com
Scilex Holding ends sales agreement, shares details - Investing.com
Scilex’s (SCLX) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Scilex Pharmaceuticals Inc. Enters into A License Agreement with RoyaltyVest Ltd -February 27, 2025 at 04:05 pm EST - Marketscreener.com
CPKC President and CEO Keith Creel to address the 2025 J.P. Morgan Industrials Conference March 13 - The Globe and Mail
Insider Traders Lose US$193k As Scilex Holding Drops - Simply Wall St
Scilex seeks FDA nod for ELYXYB in acute pain management - MSN
Scilex (NASDAQ:SCLX) Stock Price Down 1.7% – Time to Sell? - Defense World
SCLX Stock Touches 52-Week Low at $0.33 Amid Market Challenges - Investing.com
Merger Deadline Extended: Denali Capital's Strategic Move Backed by Interest-Free $180K Funding - StockTitan
Denali Capital secures extension with Scilex funding - Investing.com
The growth track for Scilex Holding Company (SCLX) has changed recently - SETE News
Analytical Lens: Exploring Scilex Holding Company (SCLX)’s Financial Story Through Ratios - The Dwinnex
D. Boral Capital analysts initates a Buy rating for Scilex Holding Company (SCLX) - Knox Daily
Scilex Holding Company [NASDAQ: SCLX] Sees Decrease in Stock Value - Knox Daily
A company insider recently sold 23,343 shares of Newell Brands Inc [NWL]. Should You Sale? - Knox Daily
Sciatica Treatment Market to Reach at a CAGR 9.7% During - openPR
A company insider recently sold 187,500 shares of Solid Power Inc [SLDP]. Should You Sale? - Knox Daily
SCLX’s Stock Market Adventure: -6.00% YTD Growth Amidst Volatility - The InvestChronicle
Scilex Holding Company Stock (SCLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):